Literature DB >> 8565783

Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe.

V Spaldin1, S Madden, D A Adams, R J Edwards, D S Davies, B K Park.   

Abstract

Oxidative metabolism of the cognition activator tacrine (1,2,3,4-tetrahydro-9-aminoacridine) is thought to be catalyzed by cytochrome P4501A2 (CYP1A2). In this study, the use of tacrine as a specific substrate to measure CYP1A2 activity in vitro was investigated. Tacrine metabolism was assessed in 16 human liver microsomal samples. Initially, the percentage conversion of tacrine to stable metabolites (i.e. 1-, 2-, 4-, and 7-hydroxytacrine) at a single time point was correlated with levels of CYP1A2 apoprotein. Apoprotein was detected by immunoquantification using a monospecific CYP1A2 antipeptide antibody. Significant correlations were seen between CYP1A2 content and the degree of 1-hydroxylation (r = 0.81, p < 0.001), 7-hydroxylation (r = 0.70, p < 0.001), and metabolism to all stable products (r = 0.82, p < 0.001). The major metabolite formed in all livers was 1-hydroxytacrine. The conversion of tacrine to this metabolite was examined in more detail. The rate of formation varied from 19.2 pmol min-1 mg-1 to 101.0 pmol min-1 mg-1. There was a significant correlation (r = 0.84, p < 0.001) between the rate of formation and CYP1A2 levels. Tacrine metabolism was also compared with the rate of formation of 3-methylxanthine, from theophylline, a reaction previously shown to be catalyzed by CYP1A2. Significant correlations were found between 3-methylxanthine formation and all quantified tacrine metabolites. The rate of 3-methylxanthine generation also correlated with CYP1A2 apoprotein levels. It is concluded, therefore, that tacrine is a valuable probe for the determination of human hepatic CYP1A2 activity in vitro.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8565783

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

1.  Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo.

Authors:  J T Larsen; L L Hansen; K Brosen
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery.

Authors:  Yin Cheong Wong; Shuai Qian; Zhong Zuo
Journal:  Pharm Res       Date:  2014-02-20       Impact factor: 4.200

Review 3.  Idiosyncratic drug reactions. Metabolic bioactivation as a pathogenic mechanism.

Authors:  M Pirmohamed; S Madden; B K Park
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

Review 4.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

5.  Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease.

Authors:  R J Fontana; T M deVries; T F Woolf; M J Knapp; A S Brown; L S Kaminsky; B K Tang; N L Foster; R R Brown; P B Watkins
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

6.  In silico screening and analysis of nonsynonymous SNPs in human CYP1A2 to assess possible associations with pathogenicity and cancer susceptibility.

Authors:  Leila Navapour; Navid Mogharrab
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.379

7.  Linear Interaction Energy Based Prediction of Cytochrome P450 1A2 Binding Affinities with Reliability Estimation.

Authors:  Luigi Capoferri; Marlies C A Verkade-Vreeker; Danny Buitenhuis; Jan N M Commandeur; Manuel Pastor; Nico P E Vermeulen; Daan P Geerke
Journal:  PLoS One       Date:  2015-11-09       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.